Otto S. Hoekstra

Active 1992–2025

137
Papers
29,341
Citations
84
h-index
136
i10-index

Citations

Citations per year for Otto S. Hoekstra1967: 1 citations1984: 1 citations1988: 1 citations1989: 1 citations1993: 1 citations1995: 1 citations1996: 5 citations1997: 12 citations1998: 14 citations1999: 38 citations2000: 36 citations2001: 32 citations2002: 28 citations2003: 52 citations2004: 73 citations2005: 64 citations2006: 81 citations2007: 123 citations2008: 96 citations2009: 142 citations2010: 133 citations2011: 176 citations2012: 154 citations2013: 148 citations2014: 175 citations2015: 168 citations2016: 195 citations2017: 248 citations2018: 275 citations2019: 978 citations2020: 1,118 citations2021: 1,151 citations2022: 968 citations2023: 681 citations2024: 1,087 citations2025: 429 citations2026: 22 citations1968–1983: no citations, so these years are not shown1985–1987: no citations, so these years are not shown1990–1992: no citations, so these years are not shown1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,367 citing papers, 18.8% of this breakdownChina: 1,104 citing papers, 8.8% of this breakdownNetherlands: 1,077 citing papers, 8.6% of this breakdownGermany: 881 citing papers, 7% of this breakdownItaly: 851 citing papers, 6.8% of this breakdownUnited Kingdom: 786 citing papers, 6.2% of this breakdownFrance: 713 citing papers, 5.7% of this breakdownSwitzerland: 419 citing papers, 3.3% of this breakdownCanada: 374 citing papers, 3% of this breakdownSpain: 364 citing papers, 2.9% of this breakdownBelgium: 330 citing papers, 2.6% of this breakdownAustralia: 319 citing papers, 2.5% of this breakdown
0%18.8%Other 23.8%

Fields

  • Medicine86.7%
  • Biochemistry, Genetics and Molecular Biology7.4%
  • Engineering1.7%
  • Immunology and Microbiology1.1%
  • Computer Science0.6%
  • Physics and Astronomy0.6%
  • Other1.9%

Topics

  • Radiomics and Machine Learning in Medical Imaging8.8%
  • Medical Imaging Techniques and Applications8.2%
  • Cancer Immunotherapy and Biomarkers5.4%
  • Lung Cancer Diagnosis and Treatment3.6%
  • Lymphoma Diagnosis and Treatment3.3%
  • Radiopharmaceutical Chemistry and Applications3%
  • Other67.7%

Coauthors

All papers

Open in search
  1. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 cited by 2,408

  2. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2014 cited by 3,292

  3. RECIST 1.1—Update and clarification: From the RECIST committee

    Authors: , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2016 cited by 1,894

  4. Imaging biomarker roadmap for cancer studies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Erich P. Huang, Brian Hutton, Edward F. Jackson, Gordon C. Jayson, Andrew Jones, Dow‐Mu Koh, Denis Lacombe, Philippe Lambin, Nathalie Lassau, Martin O. Leach, Ting-Yim Lee, Edward Leen, Jason S. Lewis, Yan Liu, Mark F. Lythgoe, Prakash Manoharan, Ross J. Maxwell, Kenneth A. Miles, Bruno Morgan, Steve Morris, Tony Ng, Anwar R. Padhani, Geoff J.M. Parker, Mike Partridge, Arvind P. Pathak, Andrew C. Peet, Shonit Punwani, Andrew R. Reynolds, Simon P. Robinson, Lalitha Shankar, Ricky A. Sharma, Dmitry Soloviev, Sigrid Stroobants, Daniel C. Sullivan, Stuart A. Taylor, Paul S. Tofts, Gillian M. Tozer, Marcel van Herk, Simon Walker‐Samuel, James Wason, Kaye J. Williams, Paul Workman, Thomas E. Yankeelov, Kevin M. Brindle, Lisa M. McShane, Alan Jackson, John C. Waterton - Nature Reviews Clinical Oncology 2016 cited by 1,078

  5. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 1,648

  6. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 cited by 483

  7. RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

    Authors: , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2016 cited by 380

  8. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2015 cited by 348

  9. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 149

  10. Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer

    Authors: , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 137

  11. PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.

    Authors: , , , , , , , , , , , , - Journal of Nuclear Medicine 2021 cited by 87

  12. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2009 cited by 1,343

  13. Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability

    Authors: , , , , , , , , , , , - Acta Oncologica 2013 cited by 425

  14. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -

    Authors: , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 107

  15. Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium

    Authors: , , , , , , , , , , - Journal of Nuclear Medicine 2020 cited by 113

  16. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma

    Authors: , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2021 cited by 146

  17. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

    Authors: , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2019 cited by 107

  18. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study

    Authors: , , , , , , , , , , , , , , , - Neuro-Oncology 2019 cited by 105

  19. Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , - Journal of Nuclear Medicine 2021 cited by 85

  20. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma

    Authors: , , , , , , , , , , , - Journal of Nuclear Medicine 2022 cited by 58

  21. An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Hutchings, Sze Ting Lee, Josée M. Zijlstra, Ronald Boellaard - Scientific Reports 2023 cited by 34

  22. Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors

    Authors: , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2019 cited by 77

  23. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 1,336

  24. Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation

    Authors: , , , , , , , , - Molecular Imaging and Biology 2016 cited by 282